文献速递新发突发、热带与寄生虫病

重复伊维菌素大规模给药控制疟疾的安全性与有效性(RIMDAMAL II):一项3期、双盲、安慰剂对照、整群随机、平行组试验

Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial.
PubMed 文献 · Lancet Infect Dis · 2025-02-04

在布基纳法索西南部14个整群中开展3期双盲安慰剂对照整群随机试验,评估重复高剂量伊维菌素大规模给药联合季节性疟疾化学预防对10岁及以下儿童疟疾发病率的影响;干预组与对照组 weekly 疟疾发病率无显著差异(发生率比0.96,95%CI 0.58-1.59;p=0.8723),干预组不良事件风险低于对照组(风险比0.63,95%CI 0.46-0.87;p=0.0049)。

要点

  • 重复高剂量伊维菌素大规模给药未降低儿童疟疾发病率(发生率比0.96,95%CI 0.58-1.59;p=0.8723)。
  • 干预组不良事件风险低于对照组(风险比0.63,95%CI 0.46-0.87;p=0.0049)。
  • 2020年干预组10岁及以下儿童血红蛋白干预前后升高幅度显著高于对照组(p=0.007)。

核心结论

  • 在研究现场将重复高剂量伊维菌素大规模给药与季节性疟疾化学预防发药整合,与安慰剂大规模给药相比未降低儿童疟疾发病率,尽管第一年干预组在给药后一周蚊虫存活率较对照组降低且干预组儿童血红蛋白总体改善更大。

研究设计与样本

  • 3期、双盲、安慰剂对照、整群随机、平行组试验,在布基纳法索西南部连续两个雨季(2019-20)开展,14个村庄或村庄分区按1:1随机抽签分配至伊维菌素或安慰剂大规模给药组。
  • 研究合格参与者为经常居住于该整群并提供书面知情同意者,于2019年7月和2020年7月入组;大规模给药合格标准为身高90 cm及以上且无其他安全排除原因(如妊娠或正在服用季节性疟疾化学预防药物),无年龄限制。
  • 每个雨季(7月至10月),干预组合格参与者每月接受高剂量口服伊维菌素大规模给药(每日三次,按身高分段约300 μg/kg),对照组每月接受口服安慰剂,最多八个治疗轮次;大规模给药由研究人员与社区卫生工作者每月为两组3-59月龄儿童实施季节性疟疾化学预防同时进行。
  • 除药师外所有参与者和研究人员对分组设盲;主要结局为10岁及以下儿童每周疟疾发病率,通过每周主动病例发现评估至第2年第16周,按意向治疗分析。

主要发现

  • 干预组儿童平均估计每周疟疾发病率每100人周为1.78(95%CI 1.24-2.53),对照组为1.84(95%CI 1.29-2.64),发生率比0.96(95%CI 0.58-1.59;p=0.8723)。
  • 干预组合格参与者不良事件风险低于对照组(风险比0.63,95%CI 0.46-0.87;p=0.0049)。
  • 临床疟疾儿童中检测到的疟原虫种类分布意外多样,505名有症状儿童中56名(11%)检出非恶性疟原虫种类;但两组间种类分布无差异(p=0.15)。
  • 2019年大规模给药后一周在干预组整群捕获的吸血冈比亚按蚊种复合体存活率较对照组整群捕获者降低(p<0.0001),但大规模给药后3周捕获的蚊虫未见此效应。
  • 总体昆虫学接种率(EIR;每人每晚感染性叮咬)两组间无差异(干预组EIR 0.010;对照组EIR 0.011;组间比0.91,95%CI 0.56-1.30;p=0.45)。

局限性

  • 混杂因素可能影响主要结局,包括试验期间疟疾发病率意外偏低(可能因政府在于干预中期向所有试验整群分发双化学成分配方ITNs)、主要发病率结局在整群间过度离散以及寄生虫和蚊虫种类高度多样。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The success of crucial vector control efforts in Africa (eg, long-lasting insecticide-treated nets [ITNs] and indoor residual spraying) are threatened by widespread insecticide resistance and insufficient effect on outdoor mosquito biting. Studies have shown that ivermectin, used for the treatment of parasitic diseases, can kill malaria vectors that feed on the blood of treated people and thus might be an effective complementary vector control tool if administered widely to communities in malaria endemic regions. We aimed to test the safety of repeated, high-dose ivermectin mass drug administration (MDA) and its efficacy for reducing malaria incidence among children when integrated with seasonal malaria chemoprevention (SMC) delivery. METHODS: We conducted a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial in southwest Burkina Faso over two consecutive rainy seasons (2019-20). 14 villages or village sectors (clusters) were randomly assigned (1:1) to ivermectin or placebo MDA by random draw, and study-eligible participants (those who regularly lived in the cluster and provided written informed consent) from all households were enrolled in July, 2019 and July, 2020. Participants were eligible for MDA if they were 90 cm in height or taller and not excluded for other safety reasons (eg, pregnancy or taking SMC drugs). There were no age restrictions for participants. Each rainy season (July to October), eligible participants from the intervention group clusters received monthly high-dose oral ivermectin MDA (three daily doses, approximately 300 μg/kg dosed by height bands) and those from the control group received monthly oral placebo MDA for up to eight treatment rounds. MDA was performed by study staff alongside community health worker administration of monthly SMC to children aged 3-59 months in both groups. All participants and study personnel, apart from the pharmacist, were masked to group assignment. The primary outcome was weekly malaria incidence in children aged 10 years and younger, as assessed by weekly active case detection until week 16 of year 2, by intention to treat. Adverse events were monitored in all MDA participants through active and passive surveillance. Blood was sampled for secondary parasitological outcomes, including analysis of parasite species distribution among malaria cases. Mosquitoes were sampled from pre-selected households in three clusters per group for secondary entomological outcomes, including analysis of blood-fed mosquito survivorship, mosquito biting rates, and entomological inoculation rates. Changes in haemoglobin pre-intervention and post-intervention in children aged 10 years and younger were assessed in 2020. The trial is registered with ClinicalTrials.gov (NCT03967054) and the Pan African Clinical Trials Registry (PACT201907479787308) and is completed. FINDINGS: The study took place from July 13, 2019, to Nov 8, 2020, with seven villages assigned to the control group and seven to the intervention group. Participants were enrolled from households in both groups in July, 2019, and July, 2020. In the intervention group, 1928 participants in 2019 and 2163 participants in 2020 were followed up, and 703 children in 2019 and 686 children in 2020 were analysed. In the control group, 1604 participants in 2019 and 1921 participants in 2020 were followed up, and 605 children in 2019 and 641 children in 2020 were analysed. MDA coverage (receiving ≥1 dose) in the enrolled population (including those who were ineligible) varied over the intervention period (68-74%), with 86-95% of participants who were eligible receiving ivermectin or placebo over the study period. 288 (47·2%) of 610 children in the control group and 312 (44·2%) of 706 children in the ivermectin group received SMC, and all clusters received new dual-chemistry Interceptor G2 ITNs containing chlorfenapyr and α-cypermethrin by government authorities in October, 2019. The average estimated weekly malaria incidence rate per 100 person-weeks among children in the intervention group was 1·78 (95% CI 1·24-2·53) and 1·84 (1·29-2·64) in the control group, and the incidence rate ratio was 0·96 (95% CI 0·58-1·59; p=0·8723). The risk of adverse events among eligible participants in the intervention group was lower than in the control group (risk ratio 0·63, 95% CI 0·46-0·87; p=0·0049). The distribution of Plasmodium spp detected in children with clinical malaria was unexpectedly diverse with non-Plasmodium falciparum species detected in 56 (11%) of 505 symptomatic children; however, species distribution did not differ between groups (p=0·15). Blood-fed Anopheles gambiae species complex mosquitoes captured in intervention group clusters the week after MDA in 2019 had decreased survival relative to those captured from control group clusters (p<0·0001), but this effect was not seen in mosquitoes captured 3 weeks after MDA. Overall entomological inoculation rates (EIRs; infectious bites per person per night) did not differ between groups (intervention EIR 0·010; control EIR 0·011; between-group ratio 0·91, 95% CI 0·56-1·30; p=0·45). In 2020, children aged 10 years and younger in the intervention group had a significantly higher increase in haemoglobin pre-intervention versus post-intervention than children in the control group (p=0·007). INTERPRETATION: Repeated high-dose ivermectin MDA integrated with SMC distributions at the study site did not reduce malaria incidence among children relative to placebo MDA, despite evidence that, compared with the control group, mosquito survivorship in the first year was reduced in the intervention group the week following MDA and overall improvements in haemoglobin were greater in children in the intervention group. Confounding factors, including unexpectedly low malaria incidence over the trial period, possibly due to government distribution of dual-chemistry ITNs to all trial clusters in the middle of the intervention period, overdispersion of the primary incidence outcome between clusters, and high parasite and mosquito species diversity, might have influenced the primary outcome. FUNDING: National Institute of Allergy and Infectious Diseases.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Somé AF, Somé A, Sougué E, et al. Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial. Lancet Infect Dis. 2025. PMID: 39919778. doi:10.1016/S1473-3099(24)00751-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。